We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
HZDs pin-point base editing platform is helping customers accelerate therapeutic development.
Base editing promises provides the capacity for precise gene modifications, which could have a substantial impact on the development of therapeutics to treat rare disease and on the next generation of cell-based therapies.
HZD has the potential to be a world leader in this field. Their work in this field will benefit society and its shareholders.
Best description I have found of Horizons focus, product line and growth potential.
IMO a good starting place for any new investors interested in HZD.
https://youtu.be/IAQlworXRAc
Yeah, happy with the price and with HZDs prospects going forward.
Onwards and upwards
93p a nice price.
GLA
Took the opportunity of the drop this morning to take my first position in HZD.
Hopefully not underwater for too long.
Someone's forgotten to turn the Algos on this morning!
Been a few £100k buys over the last couple of days.
I wonder if something is brewing...
Back in here with a 10000 buy today @99.67
I like that it is range bound.
I don't think it will be range bound for long though. As soon as the US listing moves a step closer things may well take off.
A lot of the Pharma and Bio care trusts are now breaking recent highs.
Hopefully this will catch up...
Been looking at HZD for a long time now. I know it seems range bound at the moment but can't see any reason why it doesn't recover its Pre COVID valuation over the next couple of years.
Just re-watched the CEOs proactive investors from July. Can't see any reason not to invest.
HZD's services and products will be in high demand presently and in the future.
I noticed that Abcam are also considering listing in the U.S. I suppose it’s about opening up to more investors etc. I can see a takeover by bigger companies For both Abcam and horizon in the future.
Looks like the MM's have your idea
I was hoping for a drop not a rise. Any weakness and I’m buying under 95. Otherwise will buy if listing on the USA exchange is announced.
I’m surprised that Abcam didn’t come back for another try. Having said that I think. dr Milner had a big influence,and he has now started investing on other startups in the Cambridge hub.
Definitely think the company is undervalued . As the prospects going forward have not come on the radar of the uk investors. When it’s stateside the sp will move up I expect. I feel it’s a good opportunity right now. Relatively speaking it’s new science don’t forget.
I know this company well through people I speak to. I want to hold it when the us listing is close to completed but I think that is probably a month off so patience can prevail. This company was nearly bought by Abcam a few years ago at a much higher price and when the business was less interesting. My inkling is that it is very undervalued but uk investors do not know how to value biopharma that does not make money and miss the big opportunity that us investors do not.
You should listen to the webcase Trek. These were not disappointing H1 results at all but the reality of a global catastrophe that disrupted their main clients. They expect low double digit organic revenue growth moving forwards once we are through the pandemic. That would put them among the fastest growing uk companies
Imo wait for the ADR’s to be listed. Peeps expect a lift I think once all settles this will drift. After disappointing results it’s gonna take some decent H2 numbers to change sentiment. They have cash and plenty of it now but if it’s not being converted to revenues they need to acquire. Organic growth doesn’t seem to be coming through. If they can use the ADR’s to buy a cash generative US biotech all well and good but atm not sure of the direction other than trying to make what you have last! Usual caveats.
Trek
Clarification.The next two quarters I mentioned didn’t include this one. I’m hoping for a drop to 90p for my next entry point.
I think there were no figures given out as true binding Have been licensed to use chosourse and will pay as they use different parts of the chosourse platform. So it maybe impossible to give a number. Having said that I don’t know why it was not given out as an RNS .
True binding would have had to pay an upfront fee for the license which may have been in the 10s of thousands or 100 , just my thoughts. This share is a good hold for the next few years. I expect positive figures in the next two quarters. They did very well with the tie in with mammoth.
:-).
Not in here but tonight’s presentation.
https://www.proactiveinvestors.co.uk/upload/SponsorFile/File/2020_07/1596101315_Horizon-pdf.pdf
What do you make of it seeking-1.Not on investigate either.Do you know the details.What we are likely to receive for this agreement.
This is typical of lse never quite on the ball , even without the covid problems.
Why is there no RNS on the truebinding deal from yesterday.Any one else seen it on ADVFN ?
I should think so, exposure!.